Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
Prurigo nodularis is a rare, potentially debilitating, inflammatory skin disease characterized by disfiguring skin nodules often covering extensive areas of the body, and an intense and chronic itch There are currently no approved therapeutic options Nemolizumab is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, a key neuroimmune cytokine involved in the … [Read more…]
